查看文章

Venous thromboembolism (VTE) carries a long-term risk of recurrence. Anticoagulation is administered with the aim of both treating the index VTE (initial management [first 5-21 days of diagnosis] and primary treatment [until 3-6 months]), and preventing recurrences (secondary prevention [beyond 3-6 months])[1]. Intensity and duration of anticoagulant therapy should therefore be calibrated to the individual risk profile, extending treatment until recurrence risk outweighs the risk for anticoagulant-related bleeding. The presence of specific risk factors at the time of the initial VTE event is a critical determinant of recurrence risk, and the contribution of each risk factor varies according to its magnitude and reversibility [2]. While a number of VTE risk assessment models have been developed, clinical estimation of the recurrence risk after a first episode remains primarily based on whether this is unprovoked or provoked by …